This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11120%2F08%3A00002197%21RIV11-MSM-11120___/
n14http://localhost/temp/predkladatel/
n11http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
skoshttp://www.w3.org/2004/02/skos/core#
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n10http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11120%2F08%3A00002197%21RIV11-MSM-11120___
rdf:type
skos:Concept n17:Vysledek
dcterms:description
Despite the considerable limitations of an open, non-masked trial, particularly in Menire's disease (MD), a higher dosage of betahistine-dihydrochloride and a long-term treatment seems to be more effective than a low dosage and short-term treatment. Objective. To evaluate the prophylactic effects of a low versus high dosage long-term treatment with betahistine-dihydrochloride on the number of attacks in MD. Patients and methods. We performed an open, non-masked trial, in which patients with MD received either a low dosage of betahistine-dihydrochloride (16 or 24 mg tid) or a higher dosage of 48 mg tid for at least 12 months. The outcome measure was the number of attacks per month during a 3-month period. Non-parametric tests and a random effects model were used for statistical analysis. Results. A total of 112 patients were included in the analysis: 50 received betahistine-dihydrochloride in a low dosage (16 mg tid, n=21, 24 mg, n=29) and 62 received 48 mg tid. Follow-up examination every 3 month Despite the considerable limitations of an open, non-masked trial, particularly in Menire's disease (MD), a higher dosage of betahistine-dihydrochloride and a long-term treatment seems to be more effective than a low dosage and short-term treatment. Objective. To evaluate the prophylactic effects of a low versus high dosage long-term treatment with betahistine-dihydrochloride on the number of attacks in MD. Patients and methods. We performed an open, non-masked trial, in which patients with MD received either a low dosage of betahistine-dihydrochloride (16 or 24 mg tid) or a higher dosage of 48 mg tid for at least 12 months. The outcome measure was the number of attacks per month during a 3-month period. Non-parametric tests and a random effects model were used for statistical analysis. Results. A total of 112 patients were included in the analysis: 50 received betahistine-dihydrochloride in a low dosage (16 mg tid, n=21, 24 mg, n=29) and 62 received 48 mg tid. Follow-up examination every 3 month
dcterms:title
Long-term prophylactic treatment of attacks of vertigo in Menire's disease - comparison of a high with a low dosage of betahistine in an open trial Long-term prophylactic treatment of attacks of vertigo in Menire's disease - comparison of a high with a low dosage of betahistine in an open trial
skos:prefLabel
Long-term prophylactic treatment of attacks of vertigo in Menire's disease - comparison of a high with a low dosage of betahistine in an open trial Long-term prophylactic treatment of attacks of vertigo in Menire's disease - comparison of a high with a low dosage of betahistine in an open trial
skos:notation
RIV/00216208:11120/08:00002197!RIV11-MSM-11120___
n4:aktivita
n7:N
n4:aktivity
N
n4:cisloPeriodika
5
n4:dodaniDat
n10:2011
n4:domaciTvurceVysledku
n11:8989907
n4:druhVysledku
n15:J
n4:duvernostUdaju
n13:S
n4:entitaPredkladatele
n16:predkladatel
n4:idSjednocenehoVysledku
377149
n4:idVysledku
RIV/00216208:11120/08:00002197
n4:jazykVysledku
n12:eng
n4:klicovaSlova
Meniere's disease; betahistine-dihydrochloride; attacks of vertigo; long-term treatment
n4:klicoveSlovo
n5:Meniere%27s%20disease n5:attacks%20of%20vertigo n5:long-term%20treatment n5:betahistine-dihydrochloride
n4:kodStatuVydavatele
NO - Norské království
n4:kontrolniKodProRIV
[463A14239FA0]
n4:nazevZdroje
Acta Oto-Laryngologica
n4:obor
n8:FF
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
9
n4:rokUplatneniVysledku
n10:2008
n4:svazekPeriodika
128
n4:tvurceVysledku
Hahn, Aleš
n4:wos
000255042200005
s:issn
0001-6489
s:numberOfPages
5
n14:organizacniJednotka
11120